GlassScriptPhysician profile
Bess A Whitmore
NPI 1215569314
$3,740.46
in general payments reported to CMS, 2019-2025
19 companies · $294 in 2025
The $294 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $938 · 2022: $1,131 · 2023: $698 · 2024: $679 · 2025: $294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,671.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,671.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $742.29 | 2021-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Novartis Pharmaceuticals Corporation | $538.41 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $469.43 | 2021-2024 | Xarelto |
| Pfizer INC. | $431.85 | 2021-2025 | |
| Abbvie INC. | $289.66 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $260.09 | 2021-2022 | |
| Electromed, INC. | $208.85 | 2022-2024 | Smartvest |
| Merck Sharp & Dohme LLC | $126.45 | 2021-2024 | Dificid, Zerbaxa |
| Gilead Sciences, INC. | $115.69 | 2021-2022 | |
| Paratek Pharmaceuticals, INC. | $107.36 | 2022-2024 | Nuzyra |
| Philips North America LLC | $95.23 | 2022 | |
| Alexion Pharmaceuticals, INC. | $90.15 | 2021-2023 | Ultomiris |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $69.44 | 2022-2025 | Lifevest |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.71 | 2022-2024 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $44.07 | 2024-2025 | Eliquis |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $39.17 | 2023 | Givlaari |
| Medtronic, INC. | $22.96 | 2021 | |
| Nabriva Therapeutics, Plc | $19.47 | 2021 | |
| Novo Nordisk INC | $16.18 | 2024 | Rybelsus, Ozempic |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bess Whitmore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.